We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Novartis said that Fabhalta (iptacopan) has shown meaningful and statistically significant proteinuria reduction of 38.3% versus placebo as per pre-specified interim analysis of the Phase 3 APPLAUSE-IgAN study
Germany-based Merck KGaA and Caris Discovery, the therapeutic research division of Caris Life Sciences, have signed a cancer-based antibody-drug conjugates (ADC) development deal worth up to $1.4bn. Under
Basilea Pharmaceutica has received approval from the US Food and Drug Administration (FDA) for Zevtera (ceftobiprole medocaril sodium for injection) for three different indications. The SIX Swiss Exchange-listed
Danish drugmaker Genmab has agreed to acquire ProfoundBio, a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for certain cancers, for $1.8bn. Based in Washington, ProfoundBio has a pipeline
French biopharmaceutical company Ipsen has licensed STRO-003, an antibody-drug conjugate (ADC) for solid tumours, from US-based Sutro Biopharma in a deal with a top-end value of $900m. STRO-003
Eisai has submitted the supplemental biologics license application (sBLA) to the US Food and Drug Administration (FDA) for the use of Leqembi (lecanemab-irmb) in intravenous (IV) maintenance dosing
Gilead Sciences and clinical-stage biotechnology company Xilio Therapeutics have entered into a licence agreement, worth up to $647.5m, for the latter’s XTX301, a Phase 1 Interleukin 12 (IL-12)
Akebia Therapeutics has received approval from the US Food and Drug Administration (FDA) for Vafseo (vadadustat) tablets to treat anaemia caused by chronic kidney disease (CKD). The FDA’s
Verge Genomics has forged a partnership with Ferrer, a rare neurological disorders-focused pharmaceutical company, to co-develop the former’s lead amyotrophic lateral sclerosis (ALS) drug candidate, VRG50635. VRG50635 is
US-based Nuvation Bio has agreed to acquire AnHeart Therapeutics, an oncology-focused clinical-stage biopharmaceutical firm, in an all-stock transaction. The acquisition is expected to advance Nuvation Bio as a